PIEZO-101 First-in-Human Safety and Proof-of-Concept Study

Starting soon · Early Phase 1

Conditions studied: Skin Aging, Wrinkles in Decolletage, Wrinkles in Left Knee, Left Knee Skin Laxity, Décolleté Wrinkles

In brief

The aim of this first-in-human clinical study is to explore the safety, tolerability, pharmacodynamics, and exploratory efficacy of PIEZO-101, an investigational plasmid DNA biostimulator that aims to restore expression of key proteins in the skin for extracellular matrix rejuvenation. PIEZO-101 is administered using an intradermal injection followed by localized electroporation using the investigational device Piezopen. This clinical trial will study safety and tolerability, pharmacodynamics using biopsies from the left knee, and exploratory efficacy using photography on the décolleté. Up to 8 participants may be enrolled to ensure 6 evaluable participants complete the study.

Key facts

Study ID

NCT07671027

Run by

Piezo Therapeutics, Inc.

People needed

8

Starts

2026-09-01

Expected to finish

2027-08-01

Last updated by the study team

2026-06-26

Who can join

Age: 40 and older, up to 65. Sex: female. Healthy volunteers: accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.